Consistent with the effect on CD8+ T-cell infiltration, the combination of ERK inhibition with anti-PD-1 antibodies led to significant tumor regression in tumors expressing HRSWT and HRSS345A, not in tumors expressing HRSS345D (Fig. 2d–f and Supplementary Fig. 4a, b). This evidence concerns the gene CD8A and neoplasm.